Chenodeoxycholic acid Leadiant 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
S/0022 
6th annual re-assessment 
20/07/2023 
n/a 
The CHMP, having reviewed the evidence of compliance 
with the specific obligations and the impact of the data 
submitted by the MAH on the benefit/risk profile of the 
medicinal product, concluded that the marketing 
authorisation under exceptional circumstances of 
Chenodeoxycholic acid Leadiant should be maintained. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
PSUSA/10590/
Periodic Safety Update EU Single assessment - 
12/05/2023 
n/a 
PRAC Recommendation - maintenance 
202210 
chenodeoxycholic acid (inborn error in primary bile 
acid synthesis, xanthomatosi - centrally authorised 
products only) 
S/0020 
5th annual re-assessment 
21/07/2022 
n/a 
The CHMP, having reviewed the evidence of compliance 
with the specific obligations and the impact of the data 
submitted by the MAH on the benefit/risk profile of the 
medicinal product, concluded that marketing authorisation 
of Chenodeoxycholic acid Leadiant should be maintained. 
PSUSA/10590/
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
202110 
chenodeoxycholic acid (inborn error in primary bile 
acid synthesis, xanthomatosi - centrally authorised 
products only) 
R/0018 
Renewal of the marketing authorisation. 
14/10/2021 
09/12/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Chenodeoxycholic acid Leadiant in the approved indication 
remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
S/0017 
4th annual re-assessment. 
14/10/2021 
n/a 
The CHMP, having reviewed the evidence of compliance 
with the specific obligations and the impact of the data 
submitted by the MAH on the benefit/risk profile of the 
medicinal product, concluded that marketing authorisation 
under exceptional circumstances of Chenodeoxycholic acid 
Leadiant should be maintained. 
PSUSA/10590/
Periodic Safety Update EU Single assessment - 
06/05/2021 
n/a 
PRAC Recommendation - maintenance 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
202010 
chenodeoxycholic acid (inborn error in primary bile 
acid synthesis, xanthomatosi - centrally authorised 
products only) 
IB/0015/G 
This was an application for a group of variations. 
06/01/2021 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
S/0014 
3rd annual re-assessment 
23/07/2020 
n/a 
The CHMP, having reviewed the evidence of compliance 
with the specific obligations and the impact of the data 
submitted by the MAH on the benefit/risk profile of the 
medicinal product, concluded that marketing authorisation 
under exceptional circumstances of Chenodeoxycholic acid 
Leadiant should be maintained. 
PSUSA/10590/
Periodic Safety Update EU Single assessment - 
17/04/2020 
n/a 
PRAC Recommendation - maintenance 
201910 
chenodeoxycholic acid (inborn error in primary bile 
acid synthesis, xanthomatosi - centrally authorised 
products only) 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0012 
C.I.11.z - Introduction of, or change(s) to, the 
08/01/2020 
17/12/2020 
SmPC and 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
Annex II 
PSUSA/10590/
Periodic Safety Update EU Single assessment - 
31/10/2019 
n/a 
PRAC Recommendation - maintenance 
201904 
chenodeoxycholic acid (inborn error in primary bile 
acid synthesis, xanthomatosi - centrally authorised 
products only) 
S/0010 
2nd annual re-assessment. 
17/10/2019 
n/a 
The CHMP, having reviewed the evidence of compliance 
with the specific obligations and the impact of the data 
submitted by the MAH on the benefit/risk profile of the 
medicinal product, concluded that marketing authorisation 
of Chenodeoxycholic acid Leadiant should be maintained. 
PSUSA/10590/
Periodic Safety Update EU Single assessment - 
16/05/2019 
n/a 
PRAC Recommendation - maintenance 
201810 
chenodeoxycholic acid (inborn error in primary bile 
acid synthesis, xanthomatosi - centrally authorised 
products only) 
PSUSA/10590/
Periodic Safety Update EU Single assessment - 
31/10/2018 
n/a 
PRAC Recommendation - maintenance 
201804 
chenodeoxycholic acid (inborn error in primary bile 
acid synthesis, xanthomatosi - centrally authorised 
products only) 
IA/0008/G 
This was an application for a group of variations. 
29/08/2018 
n/a 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
S/0006 
Annual re-assessment. 
26/07/2018 
n/a 
PSUSA/10590/
Periodic Safety Update EU Single assessment - 
17/05/2018 
n/a 
PRAC Recommendation - maintenance 
201710 
chenodeoxycholic acid (inborn error in primary bile 
acid synthesis, xanthomatosi - centrally authorised 
products only) 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
IB/0004 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
28/09/2017 
31/05/2018 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0003/G 
This was an application for a group of variations. 
04/07/2017 
31/05/2018 
Annex II and 
PL 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
T/0001 
Transfer of Marketing Authorisation 
12/05/2017 
31/05/2017 
SmPC, 
Labelling and 
PL 
IB/0002/G 
This was an application for a group of variations. 
12/05/2017 
31/05/2017 
SmPC, Annex 
A.2.a - Administrative change - Change in the 
(invented) name of the medicinal product for CAPs 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
II, Labelling 
and PL 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
